Why Did Adding Oxandrolone to Burn Care Fail to Improve Weight Gain?
Propranolol, oxandrolone, anabolic ceilings, and the limitations of scale weight in severe burn recovery
Key point: Failure to increase short-term body weight does not mean oxandrolone lacked anabolic activity.
The strongest explanations are a ceiling effect from propranolol and modern burn care, distortion of body weight by fluid shifts, and a treatment window too short to capture longer-term changes in lean mass and function.
The available data provide a fairly coherent explanation, and the negative "weight gain" finding does not appear to mean oxandrolone had no anabolic activity.
There are two studies worth separating first.
The July 28, 2026 MASCOTS study enrolled 813 adult burn patients across 12 US centers. It compared oxandrolone, testosterone, HGH, or no anabolic supplementation. Anabolic treatment did not significantly improve inpatient weight maintenance versus standard care, P = .064.
This study did not specifically test oxandrolone added to propranolol.
Source: MASCOTS study, PubMed
The study that directly tested oxandrolone plus propranolol against standard care was the pediatric Chao trial. It found no greater change in total body weight or lean body mass with the combination, even though muscle strength, power, protein synthesis, and net muscle protein balance improved.
Source: Oxandrolone plus propranolol trial
That distinction is important.
1. Propranolol itself is already a strong anabolic intervention in severe burns
This might be the most important explanation.
The classic propranolol burn study found:
- Propranolol increased net muscle protein balance by 82 percent.
- Controls experienced a 27 percent deterioration.
- Fat-free mass was essentially preserved with propranolol.
- Controls lost about 9 percent of fat-free mass.
The mechanism was particularly interesting.
Propranolol did not primarily stop proteolysis. Instead, beta blockade increased muscle protein synthesis and intracellular recycling of amino acids.
Source: Propranolol and muscle protein metabolism in severe burns, NEJM
Oxandrolone appears to act through a surprisingly similar downstream metabolic endpoint.
In burned children, oxandrolone increased muscle protein synthesis efficiency and improved net protein balance without significantly reducing protein breakdown.
Intracellular amino acids released from protein turnover were redirected toward protein synthesis rather than leaving the muscle cell.
Source: Oxandrolone and muscle protein metabolism
Simplified physiological model
Severe burn
→ catecholamine excess
→ increased resting energy expenditure
→ increased substrate cycling
→ muscle amino-acid loss
→ negative protein balance
Propranolol:
Lower adrenergic drive
→ lower energy expenditure
→ greater protein synthetic efficiency
→ greater intracellular amino-acid recycling
→ improved net protein balance
Oxandrolone:
Androgen receptor signaling
→ greater protein synthetic efficiency
→ greater intracellular amino-acid recycling
→ improved net protein balance
These drugs act through different upstream mechanisms, yet both ultimately improve muscle protein economy.
This raises the possibility of an anabolic ceiling.
2. Evidence for an anabolic ceiling already exists
Researchers tested growth hormone, propranolol, growth hormone plus propranolol, and standard care in severely burned children.
Propranolol improved muscle protein balance.
Adding growth hormone to propranolol produced essentially the same response.
Growth hormone did not provide a meaningful additional anabolic effect.
The researchers proposed a ceiling of anabolic effect, where propranolol had already shifted muscle protein metabolism far enough toward anabolism that another anabolic intervention had limited room to improve the measured endpoint.
Source: Growth hormone plus propranolol burn study
This phenomenon fits the oxandrolone plus propranolol findings surprisingly well.
3. Body weight is a poor endpoint in acute burn research
Burn researchers have repeatedly warned about relying on body weight.
Initial burn resuscitation often adds enormous amounts of fluid.
Subsequent diuresis is unpredictable.
Weight is influenced by:
- IV fluid resuscitation
- Edema
- Hypoalbuminemia
- Renal function
- Ventilation
- Infection
- Repeated grafting and surgery
- Inflammation
- Changes in extracellular water
These variables move scale weight independently of skeletal muscle.
Source: Nutrition and metabolic management of burn patients
A contemporary burn cohort found that patients with burns greater than 20 percent total body surface area often gained roughly 5 to 8 percent above baseline weight during the first week because of resuscitation fluid.
Source: Weight change following major burns
A later study even developed an edema-adjusted "dry weight" equation because hospital scale weights poorly represented actual tissue loss.
Source: Edema-adjusted body weight after burn injury
Consider this simple example:
| How fluid shifts distort scale weight | |
| 2 kg additional muscle retention + 5 kg fluid loss | 3 kg reduction on the scale |
| No change in muscle + 4 kg retained fluid | 4 kg apparent weight gain |
Therefore, total body weight is a weak marker of anabolic activity during acute burn recovery.
DEXA, muscle protein tracer studies, muscle strength, nitrogen balance, CT muscle area, and longer-term functional outcomes provide more useful information.
4. The OxProp trial itself demonstrates the disconnect
In the Chao trial:
| Body weight | |
| Control | 38.4 → 40.5 kg |
| Oxandrolone plus propranolol | 44.6 → 47.3 kg |
| Lean mass | |
| Control | 26.6 → 28.4 kg |
| Oxandrolone plus propranolol | 30.0 → 31.9 kg |
Both groups gained lean mass.
The magnitude of lean-mass change was statistically similar.
Yet muscle physiology told a different story.
| Functional changes | |
| Strength increase, control | +14.4 N·m |
| Strength increase, OxProp | +22.3 N·m |
| Power increase, control | +16.7 W |
| Power increase, OxProp | +30.8 W |
Muscle fractional synthetic rate was also significantly greater with OxProp after rehabilitation.
Net muscle protein balance was significantly better.
Source: Full OxProp rehabilitation study
This is strong evidence against interpreting "no additional weight gain" as "no anabolic effect."
5. The treatment window might have been too short
The Chao trial used only six weeks of rehabilitation relatively soon after the burn injury.
The investigators discussed this limitation.
Earlier studies showing larger oxandrolone-related increases in lean mass used approximately 12 weeks of exercise and studied patients later after injury.
In one earlier study:
- Exercise alone increased lean mass about 5.8 percent.
- Oxandrolone alone increased lean mass about 5.4 percent.
- Oxandrolone plus exercise increased lean mass about 13.1 percent.
In the shorter OxProp study:
- Control increased lean mass about 6.8 percent.
- OxProp increased lean mass about 6.3 percent.
The researchers specifically suggested that the shorter six-week program and earlier post-burn timing contributed to the failure to separate lean-mass outcomes.
Source: Chao et al. OxProp trial
6. Oxandrolone's larger body-composition effects appear later
Long-term oxandrolone studies have found effects months after acute hospitalization.
One pediatric study found significant differences in weight, lean mass, and bone outcomes during prolonged follow-up.
Some improvements continued after oxandrolone was discontinued.
Source: Long-term oxandrolone study
A much larger study involving 612 severely burned children also found clinically meaningful long-term effects from combined propranolol and oxandrolone therapy.
OxProp shortened post-burn growth arrest by approximately 84 days.
Growth velocity increased by approximately 1.7 cm per year versus control.
Source: Long-term OxProp outcomes
These findings occurred after prolonged treatment.
An acute inpatient weight study therefore risks looking at the wrong endpoint during the wrong period.
7. Oxandrolone does not appear to interfere with propranolol pharmacokinetics
Researchers specifically examined this possibility.
Ninety-two severely burned pediatric patients received propranolol alone or oxandrolone plus propranolol.
Oxandrolone did not significantly alter:
- Propranolol plasma concentrations
- Propranolol half-life
- Maximum propranolol concentration
- Minimum propranolol concentration
- Heart-rate response
Therefore, failure to produce additional weight gain does not appear to result from oxandrolone reducing propranolol exposure.
Source: Oxandrolone and propranolol pharmacokinetics
8. Modern standard burn care is much more anabolic than historical care
This matters when comparing older studies with newer studies.
Modern burn treatment includes:
- Earlier excision and grafting
- High-protein enteral nutrition
- Improved metabolic support
- Earlier mobilization
- Resistance rehabilitation
- Better infection control
- Improved fluid management
Contemporary patients often lose far less body weight than historical burn cohorts.
Patients with major burns now often lose less than 10 percent of baseline weight, compared with historical reports approaching 20 percent or more.
Source: Modern burn weight-loss data
This produces another ceiling effect.
If modern care already prevents much of the muscle and weight loss seen in older patients, the remaining difference available for an anabolic drug to demonstrate becomes much smaller.
9. The 2026 MASCOTS study has an important confounding issue
MASCOTS was not a randomized oxandrolone plus propranolol trial.
It was a multicenter observational analysis.
An earlier MASCOTS report showed:
- Oxandrolone median weight change: -4.0 kg
- Testosterone: -2.4 kg
- Standard care: -0.25 kg
Yet the patients receiving anabolic therapy also had substantially longer hospital stays.
Median length of stay:
- Oxandrolone: 36 days
- Testosterone: 36 days
- Standard care: 25 days
Source: MASCOTS cohort report
This raises a major possibility of confounding by indication.
Clinicians tend to prescribe anabolic therapy to patients who:
- Appear more catabolic
- Have larger or deeper burns
- Remain hospitalized longer
- Have more nutritional difficulty
- Have slower recovery
- Are failing to maintain weight
Propensity matching helps reduce this problem, but unmeasured confounding still exists.
The final 813-patient study therefore does not prove that anabolic therapy caused worse weight outcomes.
It shows that anabolic supplementation failed to demonstrate an independent inpatient weight-maintenance advantage within this real-world cohort.
Source: Final 2026 MASCOTS study
How I Interpret These Findings
I would not interpret these studies as evidence that oxandrolone "doesn't work" when propranolol is present.
A more physiologically consistent explanation is:
Severe burn hypermetabolism
→ massive catecholamine-driven energy expenditure
→ accelerated muscle protein turnover
→ negative muscle protein balance
Then:
Propranolol
→ removes a major driver of the hypermetabolic state
→ reduces metabolic expenditure
→ improves amino-acid recycling
→ improves muscle protein synthesis efficiency
→ preserves lean tissue
Oxandrolone then adds:
Androgen receptor activation
→ increased protein synthesis signaling
→ improved nitrogen retention
→ improved muscle protein balance
Once propranolol, high-protein nutrition, wound closure, and resistance rehabilitation are already in place, there is less remaining catabolism for oxandrolone to overcome.
The incremental effect of oxandrolone therefore becomes easier to detect in:
- Muscle protein kinetics
- Strength
- Power
- Growth velocity
- Long-term lean mass
- Functional recovery
It becomes harder to detect through short-term total body weight.
The Bigger Implication for Propranolol and Catabolism
These studies also tell us something important about propranolol itself.
In severe hyperadrenergic catabolism, propranolol behaves almost like an anabolic intervention.
It does not simply reduce tissue destruction.
It appears to improve muscle protein synthetic efficiency and amino-acid recycling strongly enough that adding a second anabolic stimulus sometimes produces limited additional improvement in gross body mass.
The growth hormone plus propranolol experiment provides especially strong support for this "anabolic ceiling" hypothesis.
Source: Growth hormone plus propranolol study
The newer MASCOTS findings shift the central question away from:
"Does oxandrolone affect protein metabolism?"
Evidence strongly suggests that it does.
The more relevant clinical question is:
"Does adding oxandrolone to modern burn care produce enough additional clinically meaningful benefit to justify its risks?"
The newer evidence makes this second question much less settled.
Source: 2026 MASCOTS study
Concise Clinical Takeaway
In severe burn injury, propranolol already produces a substantial anti-catabolic effect by reducing adrenergic hypermetabolism and improving muscle protein efficiency. Adding oxandrolone might improve protein synthesis, strength, power, and longer-term recovery without producing a measurable short-term increase in scale weight.
For this reason, lack of additional weight gain should not be interpreted as proof of no anabolic effect. Short-term body weight is heavily distorted by fluid shifts and is a weak endpoint for judging muscle preservation in burn patients.
The more relevant question is whether oxandrolone adds enough benefit in lean mass, strength, functional recovery, or long-term outcomes beyond modern nutrition, rehabilitation, wound care, and propranolol to outweigh its adverse effects and monitoring burden.
Prepared as an evidence-focused review for ExcelMale.com
www.vumedi.com
